Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as SAV1/WW45, PP2A, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 27/January/2019, `11.47 pm